---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-010114"
form_type: "8-K/A"
ticker: "BDSX"
cik: "0001439725"
company_name: "BIODESIX INC"
filed_at: "2026-01-12T23:59:59+00:00"
generated_at: "2026-05-16T10:50:06.858285+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Biodesix prelim Q4 rev $28.8M (+41%), FY rev $88.5M (+24%), affirms positive Adj EBITDA Q4

## Summary
- Estimated Q4 total revenue $28.8M (+41% YoY); full-year $88.5M (+24% YoY), exceeding raised guidance of $84-86M.
- Lung Diagnostics revenue $25.2M in Q4 (+47% YoY), $79.2M FY (+22% YoY); test volumes 18,000 Q4, 62,600 FY.
- Development Services revenue $3.6M Q4 (+13% YoY), $9.3M FY (+41% YoY).
- Cash $19.0M as of Dec 31, 2025, up 14% from Q3, including $2.3M ATM proceeds; core cash flat.
- Management affirms positive Adjusted EBITDA for Q4 2025 based on strong revenue flow-through.

## SEC filing metadata
- accession: 0001193125-26-010114
- form_type: 8-K/A
- ticker: BDSX
- cik: 0001439725
- company_name: BIODESIX INC
- filed_at: 2026-01-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1439725/000119312526010114/0001193125-26-010114-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1439725/000119312526010114/bdsx-20260112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-010114
- JSON: https://secwatch.observer/filing/0001193125-26-010114.json
- Plain text: https://secwatch.observer/filing/0001193125-26-010114.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.